# Blackstone Life Sciences

Blackstone Life Sciences is a Life Sciences based in Cambridge, United States.

## Overview

- **Organization type:** Life Sciences
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Founded:** 2017
- **Assets under management:** Undisclosed
- **Website:** blackstone.com
- **LinkedIn:** https://www.linkedin.com/company/blackstone-life-sciences

## Regulatory record

- **CRD number:** 304477
- **SEC file number:** 801-116920
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/304477

## About

Blackstone Life Sciences Advisors is an SEC-registered investment adviser in Cambridge, MA, registered since 2019. The firm manages $13.2 billion in assets. It has 31 employees and 21 investment advisers.

## Sectors

- Digital Health
- Healthcare Services
- Biotechnology
- Pharmaceuticals

## Offices

- London, United Kingdom
- Minneapolis, MN, United States
- Hellerup, Denmark

## Questions

### What types of investments does Blackstone Life Sciences pursue?

The group deploys capital across three primary strategies: royalty monetizations (acquiring revenue streams from approved drugs), structured credit secured by healthcare assets, and control or significant minority equity investments in commercial-stage companies. The equity strategy targets biopharma, medical devices, and healthcare technology businesses that have already achieved regulatory milestones or are generating revenue, rather than early-stage discovery bets.

### Does Blackstone Life Sciences invest in early-stage biotech?

No. The group explicitly avoids pre-clinical and Phase I venture capital. Its model targets products and companies that have cleared significant regulatory or clinical validation, providing growth capital for late-stage trials, commercialization, or market expansion. This risk posture aligns with Blackstone's broader preference for cash-flow-oriented assets.

### How does Blackstone Life Sciences source royalty deals?

The group sources royalty investments directly from biopharma companies, academic institutions, and inventors seeking to monetize future drug revenue streams without giving up equity. It also partners with companies to provide non-dilutive financing secured by royalty interests. Blackstone Life Sciences' ability to write checks exceeding $1 billion gives it an advantage in large, complex royalty transactions that smaller dedicated funds cannot underwrite.

### What is the relationship between Blackstone Life Sciences and the UK Life Sciences Innovation Fund?

In February 2025, Blackstone Life Sciences partnered with the UK government to launch a £200 million fund targeting UK-based biotech and medtech companies. The vehicle is capitalized with UK government backing and managed by Blackstone Life Sciences, combining public policy objectives with the group's commercial investment discipline. This represents a distinctive public-private collaboration model within the unit's broader strategy.

## Related profiles

- [Help At Home](https://altss.com/profile/help-at-home)
- [Sandy Spring Climate Partners](https://altss.com/profile/sandy-spring-climate-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/blackstone-life-sciences-advisors

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology